Index S&P 500
P/E 61.81
EPS (ttm) 3.00
Insider Own 0.10%
Shs Outstand 1.77B
Perf Week 7.45%
Market Cap 326.97B
Forward P/E 15.32
EPS next Y 12.08
Insider Trans -29.58%
Shs Float 1.76B
Perf Month 8.19%
Income 5.31B
PEG 9.78
EPS next Q 2.94
Inst Own 73.03%
Short Float 0.93%
Perf Quarter 10.68%
Sales 55.00B
P/S 5.94
EPS this Y -2.40%
Inst Trans 0.10%
Short Ratio 2.97
Perf Half Y 12.13%
Book/sh 4.53
P/B 40.83
EPS next Y 11.44%
ROA 4.20%
Short Interest 16.38M
Perf Year 30.49%
Cash/sh 10.23
P/C 18.10
EPS next 5Y 6.32%
ROE 55.92%
52W Range 135.85 - 186.11
Perf YTD 19.48%
Dividend Est. 6.17 (3.33%)
P/FCF 14.96
EPS past 5Y -5.77%
ROI 7.39%
52W High -0.51%
Beta 0.62
Dividend TTM 6.13 (3.31%)
Quick Ratio 0.83
Sales past 5Y 11.76%
Gross Margin 84.51%
52W Low 36.30%
ATR (14) 4.13
Dividend Ex-Date Jul 15, 2024
Current Ratio 0.94
EPS Y/Y TTM -21.01%
Oper. Margin 31.87%
RSI (14) 72.04
Volatility 3.14% 2.30%
Employees 50000
Debt/Eq 9.24
Sales Y/Y TTM -1.83%
Profit Margin 9.65%
Recom 1.83
Target Price 191.47
Option/Short Yes / Yes
LT Debt/Eq 7.97
EPS Q/Q -31.94%
Payout 220.33%
Rel Volume 1.26
Prev Close 182.17
Sales Surprise 3.14%
EPS Surprise 3.29%
Sales Q/Q 4.31%
Earnings Jul 25 BMO
Avg Volume 5.52M
Price 185.16
SMA20 8.54%
SMA50 10.72%
SMA200 14.06%
Trades
Volume 6,947,868
Change 1.64%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-05-24 Upgrade
HSBC Securities
Hold → Buy
$185
May-17-24 Initiated
Cantor Fitzgerald
Overweight
$200
Jan-29-24 Upgrade
William Blair
Mkt Perform → Outperform
Dec-18-23 Downgrade
HSBC Securities
Buy → Hold
Dec-11-23 Upgrade
Goldman
Neutral → Buy
Nov-09-23 Initiated
Deutsche Bank
Hold
$150
Oct-30-23 Upgrade
Barclays
Equal Weight → Overweight
$160 → $170
Oct-20-23 Resumed
UBS
Neutral
$157 → $150
Sep-29-23 Initiated
Raymond James
Outperform
$177
Jul-25-23 Initiated
William Blair
Mkt Perform
Jul-14-23 Initiated
HSBC Securities
Buy
$167
Apr-05-23 Downgrade
Argus
Buy → Hold
Mar-01-23 Initiated
Guggenheim
Buy
$172
Feb-22-23 Downgrade
Wolfe Research
Outperform → Peer Perform
Feb-10-23 Upgrade
SVB Securities
Underperform → Market Perform
$135 → $153
Nov-18-22 Initiated
Credit Suisse
Outperform
$170
Nov-08-22 Downgrade
Societe Generale
Buy → Hold
Aug-01-22 Downgrade
Atlantic Equities
Overweight → Neutral
$178 → $162
May-23-22 Initiated
SVB Leerink
Underperform
$140
May-06-22 Downgrade
Daiwa Securities
Outperform → Neutral
$150
Show Previous Ratings
Today 04:32AM
(Pharmaceutical Technology)
03:21AM
(Thomson Reuters StreetEvents)
02:00AM
Jul-25-24 04:25PM
04:08PM
(Investor's Business Daily)
03:30PM
Loading…
03:30PM
02:28PM
01:43PM
01:19PM
12:38PM
12:12PM
11:22AM
(The Wall Street Journal)
10:21AM
10:18AM
09:30AM
09:30AM
Loading…
09:30AM
09:00AM
(Investor's Business Daily)
08:46AM
08:45AM
08:30AM
07:46AM
(Pharmaceutical Business Review)
07:45AM
07:42AM
(Associated Press Finance)
07:39AM
07:36AM
Jul-24-24 06:08PM
03:52AM
(Pharmaceutical Technology)
Jul-23-24 08:00AM
07:02AM
Jul-22-24 10:41AM
09:49AM
Loading…
09:49AM
06:34AM
Jul-21-24 07:00AM
Jul-19-24 05:45PM
05:33PM
11:13AM
(Pharmaceutical Technology)
Jul-18-24 10:01AM
07:43AM
06:00AM
Jul-17-24 10:53AM
(Pharmaceutical Technology)
08:25AM
Jul-16-24 01:46PM
10:01AM
07:10AM
06:30AM
06:00AM
Jul-15-24 12:31PM
11:53AM
(Pharmaceutical Technology)
11:13AM
06:38AM
Jul-14-24 06:30AM
04:27AM
Jul-12-24 08:30AM
Jul-11-24 05:45PM
10:14AM
09:00AM
Jul-10-24 08:00AM
07:48AM
Jul-09-24 08:00AM
07:40AM
Jul-08-24 05:50AM
Jul-03-24 03:07PM
Jul-02-24 04:45PM
01:10PM
08:00AM
06:24AM
Jul-01-24 04:30PM
01:40PM
10:48AM
08:37AM
08:00AM
06:50AM
01:00AM
Jun-30-24 10:13AM
Jun-29-24 03:23PM
Jun-28-24 04:37PM
11:02AM
(Pharmaceutical Technology)
08:51AM
06:13AM
04:12AM
(Pharmaceutical Technology)
02:00AM
Jun-27-24 11:03AM
10:37AM
09:26AM
09:00AM
08:30AM
06:22AM
05:30AM
04:32AM
(Pharmaceutical Technology)
Jun-26-24 07:03PM
09:05AM
07:00AM
05:12AM
(Pharmaceutical Technology)
Jun-25-24 05:45PM
01:27PM
09:58AM
08:15AM
08:13AM
08:00AM
04:31AM
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GONZALEZ RICHARD A EXECUTIVE CHAIRMAN OF BOARD Jul 17 '24 Option Exercise 77.49 282,845 21,919,048 795,944 Jul 19 04:40 PM GONZALEZ RICHARD A EXECUTIVE CHAIRMAN OF BOARD Jul 17 '24 Sale 175.00 282,845 49,497,875 513,099 Jul 19 04:40 PM Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Mar 20 '24 Sale 176.30 21,082 3,716,757 55,903 Mar 22 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 18 '24 Option Exercise 61.36 26,110 1,602,110 119,890 Mar 20 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 18 '24 Sale 178.79 58,949 10,539,508 60,941 Mar 20 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 '24 Option Exercise 61.36 45,700 2,804,152 89,517 Mar 05 05:30 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 '24 Sale 177.27 75,680 13,415,503 13,837 Mar 05 05:30 PM Michael Robert A. PRES & CHIEF OPERATING OFFICER Feb 29 '24 Option Exercise 58.30 21,560 1,257,012 167,524 Mar 01 05:50 PM Michael Robert A. PRES & CHIEF OPERATING OFFICER Feb 29 '24 Sale 176.45 68,879 12,153,957 98,645 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 29 '24 Sale 177.39 9,891 1,754,555 10,397 Mar 01 05:50 PM Buckbee Kevin K SVP, CONTROLLER Feb 29 '24 Sale 176.65 5,144 908,688 6,983 Mar 01 05:50 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Feb 28 '24 Sale 177.27 138,616 24,572,458 519,099 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 23 '24 Option Exercise 137.36 13,753 1,889,115 41,926 Feb 27 05:10 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Feb 23 '24 Option Exercise 61.36 14,140 867,630 41,205 Mar 01 05:50 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Feb 23 '24 Sale 177.44 14,140 2,509,002 27,065 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 23 '24 Sale 177.51 13,753 2,441,295 28,173 Feb 27 05:10 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Feb 21 '24 Option Exercise 58.88 52,870 3,112,986 296,814 Feb 23 05:00 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Feb 21 '24 Sale 173.71 52,870 9,184,048 243,944 Feb 23 05:00 PM Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Dec 26 '23 Sale 154.72 2,912 450,545 55,903 Dec 28 05:00 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Aug 01 '23 Sale 148.58 60,000 8,914,800 565,294 Aug 02 05:07 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Jul 31 '23 Sale 149.15 18,500 2,759,275 625,294 Aug 02 05:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite